Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F (2014)

Publication Type: Journal article

Publication year: 2014

Journal

Publisher: Wiley-Blackwell

Book Volume: 232

Pages Range: 199-209

Journal Issue: 2

DOI: 10.1002/path.4287

Abstract

The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune). © 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Authors with CRIS profile

Involved external institutions

Kinki University / 近畿大学 Japan (JP) Harvard University United States (USA) (US) Royal Melbourne Hospital (RMH) Australia (AU) The University of Melbourne Australia (AU) Sapporo Medical University / 札幌医科大学 Japan (JP) Kurume University / 久留米大学 Japan (JP) Gujarat Cancer & Research Institute India (IN) National Institute for Health and Medical Research / Institut national de la santé et de la recherche médicale (INSERM) France (FR) Georges Pompidou European Hospital / Hôpital Européen Georges-Pompidou (HEGP) France (FR) Avicenne Hospital / Hôpital Avicienne France (FR) Universität Bern Switzerland (CH) Providence Portland Medical Center United States (USA) (US) Radboud University Nijmegen Netherlands (NL) Umeå University Sweden (SE) Karolinska Institute Sweden (SE) Fondazione IRCCS: Istituto Nazionale dei Tumori Italy (IT) Università degli Studi di Siena (UNISI) / University of Siena Italy (IT) Istituto Clinico Humanitas Italy (IT) Medizinische Universität Graz Austria (AT) Dorset County Hospital United Kingdom (GB) CEU San Pablo University / Universidad CEU San Pablo Spain (ES) Univerzita Karlova v Praze / Charles University in Prague Czech Republic (CZ) Cornell University United States (USA) (US) Princess Margaret Cancer Centre / Princess Margaret Hospital Canada (CA) University Health Network (UHN) Canada (CA) Keio University / 慶應義塾大学 Japan (JP) Yamaguchi University Japan (JP) Xi’an Jiaotong-Liverpool University (XJTLU) China (CN) University of Texas MD Anderson Cancer Center United States (USA) (US) Mayo Clinic United States (USA) (US) Grigore T. Popa University of Medicine and Pharmacy / Universitatea de Medicină și Farmacie "Grigore T. Popa" (UMF Iași) Romania (RO) Sidra Medical and Research Center Qatar (QA)

How to cite

APA:

Galon, J., Mlecnik, B., Bindea, G., Angell, H.K., Berger, A., Lagorce, C.,... Pages, F. (2014). Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Journal of Pathology, 232(2), 199-209. https://dx.doi.org/10.1002/path.4287

MLA:

Galon, Jerome, et al. "Towards the introduction of the 'Immunoscore' in the classification of malignant tumours." Journal of Pathology 232.2 (2014): 199-209.

BibTeX: Download